KR-20260065734-A - COMPOSITION FOR IMPROVING OR TREATING VASODILATORY OR INFLAMMATORY SKIN DISEASE COMPRISING AMPHIPATHIC BIOCOMPATABLE POLYMER

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases comprising an amphiphilic biocompatible polymer, which has excellent biocompatibility, biodegradability, collagen regeneration effect, and anti-inflammatory effect, and can be effectively used for the prevention or treatment of vasodilating or inflammatory skin diseases.

Inventors

• 이우성
• 전현진

Assignees

• 주식회사 로즈랩

Dates

Publication Date

20260511

Application Date

20251103

Priority Date

20241101

Claims (20)

1. It comprises an amphiphilic biocompatible polymer having a molecular weight of 500 g/mol to 20,000 g/mol, comprising a hydrophilic biocompatible polymer block formed of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer block formed of a hydrophobic biocompatible polymer, and A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the molecular weight ratio of the hydrophilic biocompatible polymer block and the hydrophobic biocompatible polymer block is 1:1 to 10:1.
2. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the molecular weight ratio of the hydrophilic biocompatible polymer block and the hydrophobic biocompatible polymer block is 2:1 to 5:1.
3. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the polymerization ratio of the hydrophilic biocompatible polymer and the hydrophobic biocompatible polymer is 1:1 to 10:1.
4. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the polymerization ratio of the hydrophilic biocompatible polymer and the hydrophobic biocompatible polymer is 2:1 to 8:1.
5. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the molecular weight of the amphiphilic biocompatible polymer is 3,000 to 18,000 g/mol.
6. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, comprising 0.1% to 50% by weight of the above-mentioned amphiphilic biocompatible polymer.
7. In paragraph 1, The above-mentioned amphiphilic biocompatible polymer forms vesicles within the composition, and is a pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases.
8. In Paragraph 7, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the particle size of the above-mentioned vesicles is 30 μm or less.
9. In Paragraph 7, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the particle size of the above-mentioned vesicles is 1 μm or less.
10. A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein, in claim 1, the melting point (T m ) of the amphiphilic biocompatible polymer is 35°C to 65°C.
11. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the above-mentioned hydrophilic biocompatible polymer block is formed from at least one hydrophilic biocompatible polymer selected from the group consisting of polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, poly(N-isopropylacrylamide), hyaluronic acid, dextran, derivatives thereof, and copolymers thereof.
12. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the above-mentioned hydrophobic biocompatible polymer block is formed from at least one hydrophobic biocompatible polymer selected from the group consisting of polycaprolactone, polylactic acid, polyglycolic acid, poly(3-hydroxybutyrate), polydioxanone, derivatives thereof, and copolymers thereof.
13. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the amphiphilic biocompatible polymer is a block copolymer in which the hydrophobic biocompatible polymer block is bonded to one end of the hydrophilic biocompatible polymer block.
14. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the amphiphilic biocompatible polymer is formed by polymerizing a monomer of the hydrophobic biocompatible polymer at one end of the hydrophilic biocompatible polymer block.
15. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the amphiphilic biocompatible polymer is a polyethylene glycol-polycaprolactone copolymer or a methoxypolyethylene glycol-polycaprolactone copolymer.
16. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the vasodilating skin disease is selected from the group consisting of telangiectasia, rosacea, hereditary hemorrhagic telangiectasia, ataxia telangiectasia, and facial flushing.
17. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, wherein the above-mentioned inflammatory skin disease is selected from the group consisting of rosacea, atopic dermatitis, psoriasis, lichen planus, suppurative hidradenitis, seborrheic dermatitis, and contact dermatitis.
18. In paragraph 1, A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases, provided as a topical application to the skin.
19. It comprises an amphiphilic biocompatible polymer having a molecular weight of 500 g/mol to 20,000 g/mol, comprising a hydrophilic biocompatible polymer block formed of a hydrophilic biocompatible polymer and a hydrophobic biocompatible polymer block formed of a hydrophobic biocompatible polymer, and A cosmetic composition for improving skin appearance, wherein the molecular weight ratio of the hydrophilic biocompatible polymer block and the hydrophobic biocompatible polymer block is 1:1 to 10:1.
20. In Paragraph 19, The above amphiphilic biocompatible polymer forms vesicles within the composition, a cosmetic composition for improving skin appearance.

Description

Composition for improving or treating vasodilating or inflamed skin diseases comprising an amphipathic biocompatible polymer The present invention relates to a pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases and a cosmetic composition for improving skin appearance. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases and a cosmetic composition for improving skin appearance comprising an amphiphilic biocompatible polymer. Polymeric compounds possess structures and characteristics similar to biopolymers, and efforts are being made to introduce them into disease treatment based on their high biocompatibility. As part of this initiative, research utilizing polymeric compounds to improve skin conditions or treat skin diseases is actively underway. These polymeric compounds can exert therapeutic effects through various mechanisms, such as improving skin barrier function, drug delivery, and moisturization. Polymeric compounds form a protective barrier on the skin surface to prevent moisture loss and shield the skin from external stimuli. Through this, polymeric compounds can treat various skin conditions associated with moisture loss. For example, lipid-based polymers such as ceramide are known to strengthen skin barrier function. Furthermore, polymer compounds serve as effective drug delivery systems that can enhance therapeutic effects by increasing the stability of active ingredients and improving skin penetration and bioavailability. In addition, research is being conducted on the development and application of polymer compounds with functions such as promoting wound healing, inhibiting scar formation, whitening, restoring pigmentation, anti-inflammatory effects, and antibacterial properties. In particular, topical skin preparations using polymer compounds have fewer side effects and higher safety compared to oral medications. Additionally, because they can be applied topically to specific areas, effective treatment is possible without the risk of side effects on normal skin. Rosacea is a chronic skin disease that primarily affects the central part of the face, such as the nose and cheeks, and is characterized by facial flushing and vasodilation as its main symptoms. Rosacea manifests with symptoms including flushing, vasodilation, papules, pustules, and eye irritation, and shows a high prevalence of approximately 10% in the European population, whose skin is sensitive and vulnerable to ultraviolet radiation. Excessive sun exposure, cathelicidin dysfunction, extreme weather, irritating foods, excessive alcohol consumption, excessive internal heat generation, hormonal changes, skin mites, and infections are known to be associated with the induction of rosacea; however, due to these complex triggering factors, conservative treatment aimed at alleviating and improving symptoms is currently being provided rather than a cure for the underlying cause. For example, Korean Registered Patent Publication No. 10-1187231 discloses a topical agent for rosacea treatment containing ivermectin and a polymer compound having anti-inflammatory efficacy, and Korean Published Patent Publication No. 10-2015-0004798 discloses a vesicular formulation for rosacea treatment containing a phospholipid or sulfolipid and a surfactant; however, the development of more effective therapeutic agents for the fundamental treatment of rosacea is still required. Figure 1 is an SEM (scanning electron microscope) image of an amphiphilic biocompatible copolymer in the composition of Example 1 using the copolymer of Preparation Example 8. Figure 2 is a schematic diagram of an experiment to evaluate the mast cell reduction efficacy of the example composition in an injection animal model. Figures 3a and 3b are toluidine blue stained optical microscope images showing the degree of mast cell clustering following drug treatment in an injection animal model. Figures 4a and 4b are photographs of the face before and after the application of the composition of the example to an injection patient. Figures 5a and 5b are photographs of the face before and after the application of the composition of the example to an injection patient. Hereinafter, embodiments and examples of the present invention will be described in detail with reference to the attached drawings so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in various forms and is not limited to the embodiments and examples described herein. Throughout this specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components. A pharmaceutical composition for the prevention or treatment of vasodilating or inflammatory skin diseases according